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Antimicrobial Stewardship on Hospital Discharge:
Pharmacist Intervention on Antibiotic Prescribing Practices
Jenny Zhu, PharmD, Chinh Nguyen, PharmD, and Brent Footer PharmD, BCPS
Background

Results

•

Antimicrobial Stewardship (AMS) programs were started more than 20 years
ago nationwide to combat the emergence of antimicrobial resistance.

Table 1: Patient Demographics

•

Strategies that were employed over the years to combat antimicrobial
resistance include:
o Adoption of clinical guidelines
o Education
o Formulary restriction
o Prospective audits and feedback (i.e frequency of antibiotic usage,
duration, class)

•

IDSA guidelines recommend a minimum of 5 days of antibiotics for
community acquired pneumonia (CAP), 3-5 days for uncomplicated cystitis,
7-10 days for complicated cystitis, 7-10 days for pyelonephritis, and 5 days
for non- purulent skin and soft tissue infection (SSTI)

•

2021 CDC data suggest more than 50% of antibiotic prescribing practice
across US hospitals were inappropriate

•

A prior evaluation across an Oregon hospital institution suggested patients
are potentially receiving guideline discordant and inappropriately prolonged
antibiotic treatment for the following indications:
o CAP
o Cystitis
o Pyelonephritis
o SSTI

Primary Outcome:
• Overall antibiotic duration in the pre-intervention group was longer
compared to the post-intervention group (7.4 vs. 6.4 days, respectively,
p = 0.035)
o Regardless of indication, overall duration of therapy was statistically
significant between pre-and post-intervention
Secondary Outcome:
• Duration of therapy was shorter following education in November for
the following indications:
o 2.3 days shorter in CAP
o 0.5 day shorter in uncomplicated cystitis
o 0.4 days shorter in complicated cystitis
o 1 day shorter in non-purulent SSTI
• When evaluating duration of therapy by indications, there was trend
towards shorter duration of therapy. A small sample size may have
limited the ability to detect a difference
o CAP was the only indication that was statistically significant in
showing shorter duration of therapy post education (p=0.0090)
• There was a 10.5% reduction on number of antibiotic prescribed
at discharge post-intervention compared to pre-intervention (54%
vs 64.5%, respectively, p= 0.169)

Purpose: The objective of this study was to determine if prescriber education
coupled with pharmacist assessment of antimicrobial therapy can lead to
shorter antibiotic durations of therapy within a 70-bed community hospital

Objectives

Table 2: Overall Average Antibiotic Duration of Therapy

Primary Outcome:
• Overall average antibiotic duration of therapy for the following indications:
o CAP
o Cystitis (complicated and uncomplicated)
o Pyelonephritis
o Non-purulent SSTI
Secondary Outcome: Duration of antibiotic therapy by indication and number
of patients discharged with prescriptions

Methods

• Inconsistent documentation in electronic medical records

Table 3: Average Duration of Antibiotic Therapy by Indication

Statistical Analysis:
• Chi-sqaure and Fisher's Exact test was performed for categorical variables
• T-test was performed for continuous variables

• ICD codes in Webi query did not always correlate with actual diagnosis
in patient's medical chart and further manual chart review was required

Conclusion
• Although there was no statistical difference between pre- and postintervention for specific indications, there is a trend for shorter
antibiotic therapy and reduction of antibiotic prescribed following
provider education

Intervention:
• Education initiative on November 15th and November 22nd, 2021, with
ongoing pharmacist assessment of antimicrobial therapy

Exclusion criteria:
• Bacteremia
• COVID pneumonia
• Death during hospitalization
• Transfer of care

Limitations:
• Small size (n ≤ 100) in both groups limited power to detect difference
o There is a trend for shorter duration of antibiotics prescribed post
intervention, though not statistically significant for all indications
o Complications such as sepsis, MRSA, and obesity where longer
antibiotic was indicated may affect data outcome due to sample size

Study design:
• Quasi experiment
• Pre-intervention: August 1st, 2021-October 31st, 2021
• Post-intervention: December 1st, 2021-Febuary 28th, 2022

Inclusion criteria:
• Patients >18 years old admitted with the following indications: CAP, cystitis,
pyelonephritis, and non-purulent SSTI

Patient Population:
• Demographics were similar between the two study populations
with no statistical differences (p>0.05)
o Gender: p=0.6456
o Race: p= 0.9888
• CAP was the most common indication for antibiotics (~30%), while
pyelonephritis was the least common (≤5%)

AMS program is a collaborative effort between physicians and pharmacists
in the hospital. The clinical pharmacist is responsible for:
o Reviewing empiric guidelines and literature
o Assessing antibiotic choice, duration, and dose
o Proposing recommendations as appropriate during medical
rounding, chart review, and order verification

•

Discussion

• Trend in data suggests pharmacy education and on-going discussion with
physicians is beneficial on antimicrobial prescribing practices

Figure 1 : Percentage of Patients Discharge on Antibiotics by
Indication

Going Forward
•

Evaluate data for most utilized antibiotic per indication

•

Assess impact of obesity and diabetes on duration of antibiotic therapy

•

Complete data analysis on prescribing patterns between physicians

•

Compare and contrast antibiotic duration therapy between patients with and
without Ivents opened during hospitalization
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